Rapamycin for Anti-Aging & Longevity: PEARL Trial, Dosage & Evidence (2026)
Rapamycin is the most consistent lifespan-extending drug across species: it works in yeast, worms, flies, and mice, with the ITP confirming 10-25% median lifespan extension across multiple mouse strains and labs. The PEARL trial (2025) was the first 48-week placebo-controlled human study and found that low-dose weekly rapamycin (5-10 mg) was well-tolerated, with adverse events similar to placebo. Women on 10 mg/week gained roughly 6% lean tissue mass and reported less pain. But no human trial has demonstrated that rapamycin extends lifespan or reverses biological aging. It requires a prescription, costs $50-200/month plus physician oversight, and carries real risks including mouth sores, impaired wound healing, and potential immune effects. For people seeking to target the mTOR aging pathway without a prescription, the OTC alternatives are exercise (which naturally modulates mTOR through AMPK activation) and NMN (which addresses the complementary NAD+ aging pathway).
- Rapamycin inhibits mTOR, the nutrient-sensing pathway that shifts cells from growth to repair. This is the same shift that caloric restriction triggers. No other drug has matched rapamycin's consistency across lifespan-extension studies in model organisms.
- The PEARL trial (2025, n=114, 48 weeks) established safety: adverse events were comparable to placebo at 5-10 mg/week. The 10 mg/week group showed improved lean tissue (+6%) and reduced pain in women. No lifespan or biological aging endpoint was measured.
- Marmoset studies (2024-2025) showed rapamycin slowed brain aging, retinal decline, and cardiac remodeling in a non-human primate. Dog Aging Project (TRIAD) showed improved cardiac function in middle-aged dogs. Both are stronger translational signals than mice alone.
- Side effects at longevity doses: mouth sores (most common, typically mild), potential immune modulation, lipid and glucose changes requiring monitoring. Daily high-dose transplant regimens cause serious immunosuppression; intermittent low-dose longevity protocols appear meaningfully different in safety profile.
- The RAPA-EX trial (Stanfield et al., 2026, J Cachexia Sarcopenia Muscle) tested rapamycin alongside exercise in older adults. Results were mixed, with some evidence of preserved muscle quality but no clear synergy.
- Off-label longevity dose: typically 3-10 mg once weekly (not daily). Cost: $50-200/month for compounded rapamycin, plus physician consultation ($150-500). Generic sirolimus is available but bioavailability varies between formulations.
- For OTC alternatives: berberine activates AMPK (which inhibits mTOR indirectly). NMN targets the complementary NAD+ pathway. Exercise naturally modulates both mTOR and AMPK. These are accessible starting points while monitoring rapamycin trial developments.
What Is Rapamycin and Why Do Longevity Researchers Care?
Rapamycin (sirolimus) was discovered in 1972 from soil bacteria (Streptomyces hygroscopicus) on Easter Island (Rapa Nui). It is FDA-approved as an immunosuppressant for organ transplant recipients and for treating certain cancers. Its relevance to aging comes from its target: mTOR (mechanistic target of rapamycin), a nutrient-sensing kinase that regulates cell growth, autophagy, and protein synthesis.
When mTOR is active, cells grow and divide. When mTOR is inhibited, cells shift to maintenance, repair, and autophagy (cellular cleanup). This growth-to-maintenance switch is one of the central mechanisms identified in the 12 hallmarks of aging. Caloric restriction, fasting, and exercise all partially inhibit mTOR. Rapamycin does it pharmacologically.
What makes rapamycin unique in longevity science: the ITP (Interventions Testing Program), the most rigorous multi-site aging trial in rodents, has replicated rapamycin's lifespan extension across multiple mouse strains, doses, and labs. No other compound has achieved this level of replication. The extension is typically 10-25% of median lifespan, and it works even when started late in life (equivalent to age 60+ in humans).
What Did the PEARL Trial Show About Rapamycin?
The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging in April 2025 (Moel et al., PMID 40188830), was the first placebo-controlled, year-long human study of rapamycin for healthy aging.
Design: 114 adults aged 50-85, randomized to placebo, 5 mg/week, or 10 mg/week of compounded rapamycin for 48 weeks. Primary endpoint: visceral adiposity (DXA scan). Secondary: blood biomarkers, lean tissue, bone mineral content.
Results: adverse events were comparable to placebo across all groups. Women on 10 mg/week gained approximately 6% lean tissue mass from baseline and reported reduced pain scores. Visceral fat changes did not reach significance. Blood biomarkers showed modest shifts in lipids and glucose that require monitoring but did not trigger clinical concern.
What PEARL does not show: lifespan extension, biological age reversal, or disease prevention. The trial was designed as a safety study, not an efficacy study. A 2025 George Washington University evidence review concluded that human anti-aging benefit from rapamycin remains unproven.
Does Rapamycin Work Beyond Mice?
The translational gap between mice and humans is the central challenge for rapamycin. Two recent developments help bridge it.
Marmoset studies (2024-2025): Rapamycin slowed multiple aging biomarkers in common marmosets, a non-human primate. Improvements included reduced brain aging, preserved retinal function, and attenuated cardiac remodeling. Marmosets live 10-15 years with closer physiological similarity to humans than mice. These are the strongest mammalian non-rodent data for rapamycin as a geroprotector.
Dog Aging Project (TRIAD): The ongoing trial is testing rapamycin in companion dogs. Preliminary data showed improved cardiac function and physical activity in middle-aged dogs treated with rapamycin versus placebo. Dogs share human living environments, diets, and veterinary care, making them a uniquely relevant model. Full longevity data is years away.
How Does Rapamycin Compare to NMN?
Rapamycin and NMN target different hallmarks of aging and are sometimes used together in longevity protocols.
Pathway: Rapamycin inhibits mTOR (nutrient sensing, autophagy). NMN restores NAD+ (sirtuin activity, DNA repair, mitochondrial function). These are complementary, not competing.
Human evidence: Rapamycin has PEARL (1 trial, 48 weeks, safety focus). NMN has 30+ published human trials including a 2026 Nature Metabolism head-to-head confirming NAD+ doubling.
Access: Rapamycin requires a prescription and physician monitoring. NMN is OTC.
Exercise interaction: The RAPA-EX trial (2026) showed mixed results for rapamycin combined with exercise. NMN has not shown exercise-blunting effects; the Morifuji 2024 trial showed improved walking speed at 250 mg/day.
Cost: Rapamycin $50-200/month + physician. NMN $30-60/month OTC. See our best NMN supplements guide.
Side effects: Rapamycin causes mouth sores, lipid changes, potential immune effects. NMN shows no serious adverse events in published trials up to 1,250 mg/day.
For comparison with metformin (another prescription option) and peptides, see our dedicated analyses.
What Are the Side Effects of Rapamycin at Longevity Doses?
Mouth sores (aphthous ulcers) are the most common side effect, reported by 10-30% of users at longevity doses. They are typically mild and resolve with dose adjustment or topical treatment. Some physicians prescribe dexamethasone mouthwash prophylactically.
Lipid changes: Rapamycin can raise LDL cholesterol and triglycerides. PEARL showed modest lipid shifts. Regular monitoring and potential statin co-prescription are standard in longevity protocols.
Glucose metabolism: mTOR inhibition can impair insulin signaling. At longevity doses, this effect appears mild, but fasting glucose and HbA1c should be monitored.
Immune modulation: At transplant doses (daily, high-dose), rapamycin is a potent immunosuppressant. At longevity doses (weekly, low-dose), the Mannick et al. trials (2014, 2018) actually showed improved immune response to influenza vaccination. The dose-response curve is complex. Intermittent dosing appears to avoid the immunosuppression seen with chronic daily use.
Wound healing: Rapamycin can slow wound healing. Longevity physicians typically recommend pausing rapamycin 1-2 weeks before planned surgery or dental procedures.
The risk framework: rapamycin at longevity doses is meaningfully safer than at transplant doses. But it is not risk-free, and it requires physician monitoring (bloodwork every 3-6 months). The benefit-to-risk calculation depends on your baseline health, age, and whether you are getting enough from exercise and OTC supplements before adding a prescription drug. We cover those lower-risk options first in our guide to the best anti-aging supplements.
What Is the Rapamycin Dosage for Longevity?
No FDA-approved longevity dose exists. Off-label protocols typically use 3-10 mg once weekly (not daily). PEARL tested 5 mg and 10 mg weekly. The Mannick immune trials used 0.5 mg daily or 5 mg weekly everolimus (a rapamycin analog).
Most longevity physicians start at 3-5 mg weekly and titrate based on blood levels, side effects, and biomarker response. Extended-release compounded formulations are sometimes used. Generic sirolimus (FDA-approved for transplant) is available but bioavailability varies between manufacturers.
Timing: typically taken once weekly on a consistent day. Some physicians recommend taking it with a fatty meal to improve absorption. There is no established best day or time, though some users prefer taking it on a rest day from exercise.
Cost: compounded rapamycin from specialty pharmacies runs $50-200/month depending on dose and formulation. Generic sirolimus with insurance may be cheaper but is prescribed off-label. Physician consultation adds $150-500 per visit.
Should You Take Rapamycin for Longevity?
The honest 2026 assessment: rapamycin has the strongest preclinical longevity evidence of any compound. The PEARL trial showed it is safe at longevity doses for 48 weeks. Marmoset and dog data are encouraging. But no human trial has shown it extends lifespan, reverses biological aging, or prevents age-related disease.
Consider rapamycin if: you have optimized lifestyle (exercise, sleep, diet) and core supplements, you are working with a qualified longevity physician, you can commit to regular bloodwork monitoring, and you understand this is an off-label, evidence-informed decision, not an evidence-proven one.
Start elsewhere if: you are not exercising consistently (exercise targets mTOR and AMPK naturally), you want an OTC starting point (NMN for NAD+ restoration, berberine for AMPK activation), you are not ready for the cost and monitoring requirements of prescription longevity protocols.
For a complete comparison of all anti-aging treatments ranked by evidence, see our treatments and technology guide. For the latest trial developments, see longevity research news.
Frequently Asked Questions
Is rapamycin safe for anti-aging?
The PEARL trial (2025) showed that low-dose weekly rapamycin (5-10 mg/week) had adverse events comparable to placebo over 48 weeks in healthy adults aged 50-85. This is the best safety data available for longevity-dose rapamycin. However, 48 weeks is not long-term by pharmaceutical standards, and no trial has assessed safety over 5-10 years of continuous use. Known risks at longevity doses include mouth sores, lipid elevation, and potential immune modulation. At transplant doses (daily, high-dose), rapamycin is a potent immunosuppressant, but the intermittent low-dose protocols used for longevity appear meaningfully different. Regular bloodwork monitoring (lipids, glucose, CBC) every 3-6 months is standard practice among longevity physicians.
What is the best rapamycin dose for longevity?
No validated longevity dose exists. PEARL tested 5 mg and 10 mg once weekly. Most longevity physicians prescribe 3-10 mg once weekly, starting low and titrating based on blood levels (trough levels below 3 ng/mL are typical targets). Some use biweekly dosing. The Mannick immune trials used everolimus (a rapamycin analog) at 0.5 mg daily or 5 mg weekly. Generic sirolimus bioavailability varies between manufacturers, which is why some physicians prefer compounded rapamycin with validated dissolution testing.
Can I take rapamycin and NMN together?
There is no known pharmacological interaction. Rapamycin inhibits mTOR; NMN restores NAD+. These are complementary aging pathways. Some longevity physicians recommend both: rapamycin weekly for mTOR modulation, NMN daily for NAD+ restoration. This combination has not been tested in a clinical trial, but mechanistically it covers two of the most validated aging pathways simultaneously. For NMN dosing, see our timing guide.
Does rapamycin interfere with exercise?
The RAPA-EX trial (Stanfield et al., 2026) tested rapamycin alongside exercise in older adults. Results were mixed: some evidence of preserved muscle quality but no clear synergy or interference. This is different from metformin, which the MASTERS trial showed clearly blunts muscle hypertrophy. The current evidence suggests rapamycin is more exercise-compatible than metformin, but this conclusion is preliminary and based on one small trial.
How does rapamycin compare to metformin for anti-aging?
Rapamycin has stronger preclinical evidence (consistent lifespan extension across all species tested, ITP-replicated). Metformin has a longer human safety track record (60+ years in diabetic populations) and is much cheaper ($4/month vs $50-200/month). Metformin blunts exercise; rapamycin does not clearly do so. The TAME trial will provide metformin's first aging-specific human data. PEARL provided rapamycin's first long-term safety data. Neither has demonstrated human lifespan extension. For the complete metformin analysis, see our dedicated article.
Where do I get rapamycin for longevity?
Rapamycin requires a physician's prescription. Longevity medicine physicians (available through telehealth platforms or in-person longevity clinics) prescribe it off-label. Compounding pharmacies prepare it at specified doses. Generic sirolimus is available at retail pharmacies but is typically prescribed for transplant indications. Cost: the drug itself is $50-200/month depending on dose and source; physician consultation adds $150-500 per visit. Insurance does not cover off-label longevity use.
Sources
- Moel M, et al. "Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial." Aging. 2025;17(4):908-936. PubMed
- Roark B, Iffland K. "Rapamycin for longevity: the pros, the cons, and future perspectives." Frontiers in Aging. 2025. PMC
- Stanfield KM, et al. "Exercise and weekly sirolimus in older adults: RAPA-EX-01." J Cachexia Sarcopenia Muscle. 2026. DOI
- Christen S, et al. "NAD+ boosters head-to-head." Nature Metabolism. 2026;8(1):62-73. PubMed
- Mannick JB, et al. "mTOR inhibition improves immune function in the elderly." Sci Transl Med. 2014;6(268):268ra179. PubMed
- Mannick JB, et al. "TORC1 inhibition enhances immune function and reduces infections in the elderly." Sci Transl Med. 2018;10(449):eaaq1564. PubMed
- Barzilai N, et al. "Metformin as a tool to target aging." Cell Metabolism. 2016;23(6):1060-1065. PubMed
- Salive ME, et al. "DPP 21-year follow-up: lifestyle vs metformin." JAMA. 2026;336(7):577-586. PubMed
Related reading: Metformin for Anti-Aging · Anti-Aging Peptides vs NMN · All Anti-Aging Treatments Ranked · How to Reverse Aging · Best NMN Supplements
Want to see YourHealthier first when you search Google? Add us as a preferred source.
Add to Preferred SourcesSources verified: All PubMed citations and external references in this article were last verified on September 13, 2026.
Disclosure: YourHealthier manufactures and sells the supplements discussed in this article. All health claims are based on published peer-reviewed research cited above. We earn revenue from product sales linked in this article.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
Want to see YourHealthier first when you search Google? Add us as a preferred source.